<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl1" position="float">
 <label>Table 1</label>
 <caption>
  <title>Summary of MS-Based Proteome, Lipidome, and Metabolome analyses in COVID-19 Patients</title>
 </caption>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">proteomics in COVID-19 study</th>
    <th style="border:none;" align="center">technique (sample)</th>
    <th style="border:none;" align="center">sample preparation</th>
    <th style="border:none;" align="center">sources</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td style="border:none;" align="left">Identified protein–protein interactions between SARS-CoV-2 and human proteins</td>
    <td style="border:none;" align="left">Affinity purification LC–MS (Vero E6 and HEK 293T cells)</td>
    <td style="border:none;" align="left">Samples were resuspended in 4% formic acid and 2% acetonitrile solution and separated by a reversed-phase gradient over a Nanoflow C18 column. Q-Exactive Plus mass spectrometer was used for data acquisition.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref38">38</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Identified peptide sequence from SARS-CoV-2 nucleoprotein</td>
    <td style="border:none;" align="left">Nano-HPLC/Nano-ESI-Orbitrap-MS/MS (gargle solution)</td>
    <td style="border:none;" align="left">The protocol consists of an acetone precipitation and tryptic digestion of proteins contained within the gargle solution.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref44">44</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: APOA1, APOA2, APOH, APOL1, APOD, and APOM</td>
    <td style="border:none;" align="left">TMT MS (serum)</td>
    <td style="border:none;" align="left">Ethanol used for virus inactivation, serum was lysed using 50 μL of lysis buffer (8 M urea in 100 mM 680 triethylammonium bicarbonate, TEAB), reduced in 10 mM tris(2-carboxyethyl)phosphine (TCEP), alkylated by 40 mM iodoacetamide (IAA) in darkness, dilution done with 100 mM TEAB, and digestion with double-step trypsinization.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref39">39</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: NPC2, APOA1, and CUBN</td>
    <td rowspan="2" style="border:none;" align="left">LC–MS/MS (urine)</td>
    <td rowspan="2" style="border:none;" align="left">5 mM dithiotheitol (DTT) used for virus inactivation. Urine samples were alkylated with 10 mM iodoacetamide in darkness. Proteins were digested with trypsin, and then the digestion reaction was terminated by 1% formic acid (FA) and the digested peptides were desalted and dried before LC–MS/MS analysis.</td>
    <td rowspan="2" style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref40">40</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: C3, CREB3L3, HYOU1, and SERPIND1</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Detected tryptic peptides of SARS-CoV-2 proteins (NCAP, VME1)</td>
    <td style="border:none;" align="left">Orbitrap MS (Vero E6 cell)</td>
    <td style="border:none;" align="left">Infected cells were boiled at 95 °C for 20 min to inactivate the virus. Cells were lysed with cell lysis buffer, and proteins were reduced and alkylated with DTT and IAA reagent, respectively, and precipitated using chloroform/methanol.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref41">41</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: A1BG, ACTB, C1R, C1S, C8A, CD14, CFB, CFH, CFI, CRP, FGA, FGB, FGG, HP, ITIH3, ITIH4, LBP, LGALS3BP, LRG1, SAA1, SAA2, and SERPINA10</td>
    <td rowspan="2" style="border:none;" align="left">LC–MS (plasma/serum)</td>
    <td rowspan="2" style="border:none;" align="left">8 M urea, 100 mM ammonium bicarbonate (ABC), and 4.5 mM dithiothreitol (DTT) were used for plasma/serum sample denaturation/reduction. IAA was used for alkylation, and digestion was carried out with trypsin.</td>
    <td rowspan="2" style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref42">42</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: ALB, APOA1, APOC1, TF, and GSN</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Identified nsp9 and nsp10 protein of SARS-COV-2 interact with host NKRF</td>
    <td style="border:none;" align="left">LC–MS (patients PBMC)</td>
    <td style="border:none;" align="left">PBMC cells were lysed by urea buffer to denature the proteins and sonicated twice on ice to break the protein–protein or DNA–protein interactions. TCEP (5 mM) and iodoacetamide (10 mM) were used for reduction and alkylation, respectively.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref43">43</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Spectral comparison and multivariate analysis identified distinct cluster between SARS-CoV-2 detectable versus undetectable nasal samples.</td>
    <td style="border:none;" align="left">MALDI-TOF (nasopharyngeal swabs samples)</td>
    <td style="border:none;" align="left">1 μL of sample + 1 μL of HCCA matrix (a solution containing α-cyano-4-hydroxycinnamic acid diluted into 500 μL of acetonitrile, 250 μL of 10% trifluoroacetic acid, and 250 μL of HPLC grade water) for protein extraction.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref46">46</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: Nucleotide metabolism pool</td>
    <td style="border:none;" align="left">LC–MS (Caco-2 cell)</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref45">45</xref>)
    </td>
   </tr>
  </tbody>
 </table>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">glycomics in COVID-19 study</th>
    <th style="border:none;" align="center">technique (sample)</th>
    <th style="border:none;" align="center">sample preparation</th>
    <th style="border:none;" align="center">sources</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td style="border:none;" align="left">Identified N-, O-, N-and O-Glycosylation and Fucosylation on hACE2</td>
    <td style="border:none;" align="left">Ion-Trap MS (HEK 293 cell)</td>
    <td style="border:none;" align="left">Purified hACE2 was expressed in HEK293 cells in 50 mM ammonium bicarbonate solution. Sample reduction, alkylation, and digestion were done by 25 mM DTT, 90 mM IAA, and trypsin, respectively.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref49">49</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Identified glycan mimic polypeptide epitope that modulate SARS-CoV-2 spike protein and host ACE2 receptor interactions</td>
    <td style="border:none;" align="left">LC–MS (HEK 293F cell)</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref50">50</xref>)
    </td>
   </tr>
  </tbody>
 </table>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">lipidomics in COVID-19 study</th>
    <th style="border:none;" align="center">technique (sample)</th>
    <th style="border:none;" align="center"> </th>
    <th style="border:none;" align="center">sources</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td style="border:none;" align="left">Upregulated: Diglycerides (DGs), free fatty acids (FAAs), and triglycerides (TGs)</td>
    <td rowspan="2" style="border:none;" align="left">LC–ESI–MS/MS (Plasma)</td>
    <td rowspan="2" style="border:none;" align="left">50 μL of plasma/serum homogenized with 1 mL solvent mixture (include methanol, MTBE and internal standard mixture) for lipid extraction.</td>
    <td rowspan="2" style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref95">95</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: Phosphatidylcholines (PCs)</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: Phosphotidycholine (PC) and 21-hydroxypregnenolone, the essential intermediate for synthesizing corticosterone</td>
    <td rowspan="2" style="border:none;" align="left">UPLC–MS/MS (Sera)</td>
    <td rowspan="2" style="border:none;" align="left">Serum samples were treated with ethanol for viral deactivation. Ice-cold 100% methanol was used for metabolite extraction.</td>
    <td rowspan="2" style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref39">39</xref>, 
     <xref ref-type="bibr" rid="ref129">129</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: Glycerophospholipid and sphingolipids</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: Hyperlipidemia</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref82">82</xref>)
    </td>
   </tr>
  </tbody>
 </table>
 <table frame="hsides" rules="groups" border="0">
  <colgroup>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
   <col align="left"/>
  </colgroup>
  <thead>
   <tr>
    <th style="border:none;" align="center">metabolomics in COVID-19 study</th>
    <th style="border:none;" align="center">technique (sample)</th>
    <th style="border:none;" align="center"> </th>
    <th style="border:none;" align="center">sources</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td style="border:none;" align="left">Discriminated metabolites: TCA cycle, carbamoyl phosphate of urea cycle, and guanosine monophosphate (GMP) of nucleotide biosynthesis pathways.</td>
    <td style="border:none;" align="left">LC–ESI–MS/MS (Plasma)</td>
    <td style="border:none;" align="left">3 volumes of ice-cold methanol were added to 1 volume of plasma/serum for protein precipitation and metabolite extraction.</td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref95">95</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: kynurenine pathway with elevated kynurenate, kynurenine, 8-methoxykynurenate in COVID-19 patients.</td>
    <td rowspan="2" style="border:none;" align="left">UPLC–MS/MS (Sera)</td>
    <td rowspan="2" style="border:none;" align="left">Serum samples were treated with ethanol for viral deactivation. Ice-cold 100% methanol was used for metabolite solubilization and extraction.</td>
    <td rowspan="2" style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref39">39</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: choline and its derivative phosphocholine as well as global suppression of amino acids and derivatives such as glutamate, arginine, 
     <italic>N</italic>-(
     <italic>I</italic>-arginino)succinate, citrulline, ornithine, glutamine, 2-oxoglutarate, 
     <italic>N</italic>-acetyl-
     <sc>l</sc>-glutamate, urea, fumarate, argininate, asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine, and 
     <italic>N</italic>-acetylarginine
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Upregulated: kynurenine, glucose, and free fatty acids</td>
    <td rowspan="2" style="border:none;" align="left">UHPLC–MS (Sera)</td>
    <td rowspan="2" style="border:none;" align="left">Sera were extracted via a modified Folch method (chloroform/methanol/water 8:4:3). Twenty μL of serum was diluted in 130 μL of LC–MS-grade water and then 600 μL of ice-cold chloroform/methanol (2:1) mixture were used for metabolite extraction.</td>
    <td rowspan="2" style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref130">130</xref>)
    </td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Downregulated: Nitrogen metabolism including creatine, creatinine, polyamine, and circulating amino acids</td>
   </tr>
   <tr>
    <td style="border:none;" align="left">Identified NAD dysregulation in COVID-19 patient’s</td>
    <td style="border:none;" align="left">LC–MS/MS (A549 cell)</td>
    <td style="border:none;" align="left"> </td>
    <td style="border:none;" align="left">(
     <xref ref-type="bibr" rid="ref98">98</xref>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
